Table 3.
Further treatment after EGFR‐TKI failure according to biopsy results
| Result of re‐biopsy/liquid biopsy | ||||||
|---|---|---|---|---|---|---|
| Further treatment | Consistent with baseline | Mut plus T790M/T790M | Wild type | Others | Total | P |
| 3‐TKIs | 6 (5.5)/2 (6.5) | 56 (52.3)/24 (75.0) | 1 (5.9)/1 (4.0) | 1 (12.5)/1 (50.0) | 64 (26.4)/28 (31.1) | <0.001/<0.001 |
| TKI + chemotherapy/radiotherapy | 16 (14.5)/6 (19.4) | 5 (4.7)/1 (3.1) | 2 (11.8)/3 (12.0) | 1 (12.5)/0 (0.0) | 24 (9.9)/10 (11.1) | |
| Other TKIs | 4 (3.6)/2 (6.5) | 1 (0.9)/0 (0.0) | 0 (0.0)/1 (4.0) | 2 (25.0)/0 (0.0) | 7 (2.9)/3 (3.3) | |
| Former TKIs | 6 (5.5)/3 (9.7) | 4 (3.7)/1 (3.1) | 4 (9.5)/3 (12.0) | 0 (0.0)/0 (0.0) | 11 (4.5)/7 (7.8) | |
| Chemotherapy/radiotherapy | 73 (66.4)/17 (54.8) | 35 (32.7)/5 (15.6) | 12 (70.6)/17 (68.0) | 3 (37.5)/0 (0.0) | 123 (50.8)/40 (44.4) | |
| Others | 5 (4.5)/1 (3.2) | 6 (5.6)/1 (3.1) | 1 (5.9)/0 (0.0) | 1 (12.5)/0 (0.0) | 13 (5.4)/2 (2.2) | |
Other tyrosine kinase inhibitors (TKIs) refers to other first or second‐generation EGFR‐TKIs; Other includes best supportive treatment, traditional Chinese medicine, crizotinib, etc. 3‐TKIs, third‐generation TKIs.